Tata India Pharma & Healthcare Fund Direct Growth
Tata India Pharma & Healthcare Fund Direct Growth

Tata India Pharma & Healthcare Fund Direct Growth

Compare
Equity
Direct
Sector - Healthcare

NAV: ₹ 17.5 as on 24-03-2023

Fund Performance
zero opening, trading, fund transfer fee
938 people have invested ₹ 22.5L in mutual fund in the last three months

Fund Insights

Insights icon

In the last 1 year, SBI Healthcare Opportunities Fund Direct Growth has given -2.81% return, outperforming Tata India Pharma & Healthcare Fund Direct Growth by 5.33%

Insights icon

In the last 3 years, DSP Healthcare Fund Direct Growth has given 29.51% return, outperforming Tata India Pharma & Healthcare Fund Direct Growth by 5.25% per annum

Insights icon

In the last 5 years, Nippon India Pharma Fund - Direct Plan - Growth Plan has given 16.07% return, outperforming Tata India Pharma & Healthcare Fund Direct Growth by 0.64% per annum

Insights icon

Over the last 1 year, Tata India Pharma & Healthcare Fund Direct Growth has decreased expense ratio by 7.3% moving from 1.09 to 1.01

Insights icon

Tata India Pharma & Healthcare Fund Direct Growth has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.01% which is lower than the category average expense ratio of 1.67%

INDmoney Rank

Powered by IND quant engine
IND ranking is not available for this fund.

Pros

5Y returns in the top 25% of the category

Beats FD returns for both 3Y & 5Y duration

Cons

3Y returns in the bottom 25% of the category

Tata India Pharma & Healthcare Fund Direct Growth Performance as on (24-Mar-23)

Return
1M
3M
6M
1Y
3Y
5Y
Tata India Pharma & Healthcare Fund Direct Growth
-2.4%
-6.6%
-3.6%
-8.1%
24.3%
15.4%
Nifty 500
-1.9%
-7.4%
-3%
-2.5%
26.8%
9.7%
sector - healthcare
-2%
-6.9%
-4.6%
-9.8%
24.5%
14.1%

About the Fund

Tata India Pharma & Healthcare Fund Direct Growth is an equity fund. This fund was started on  28 December, 2015. The fund is managed by Meeta Shetty. The fund could potentially beat inflation in the long-run.

Key parameters

1) Tata India Pharma & Healthcare Fund Direct Growth has a NAV of 17.4836 as on 24-03-2023.

2) Tata India Pharma & Healthcare Fund Direct Growth has 486 Cr worth of assets under management (AUM) as on 31-01-2023 and is less than category average.

3) The fund has an expense ratio 1.01 %.

Tata India Pharma & Healthcare Fund Direct Growth Overview

Expense ratio
Expense ratio
1.01%
Benchmark
Benchmark
S&P BSE Healthcare PR
AUM
AUM
₹486 Cr
Inception Date
Inception Date
28 December, 2015
Min Lumpsum/SIP
Min Lumpsum/SIP
₹5000/₹150
Exit Load
Exit Load
0.25%
Lock In
Lock In
No Lock-in
TurnOver
TurnOver
32.08%

Fund Distribution as on (28-Feb-23)

  • Equity 98.3%

  • Debt & Cash 1.7%

Size breakup

Large cap
46.3%
Mid cap
33.2%
Small cap
18.8%

Sector Allocation

Feb'23

Jan'23

Dec'22

Health

100%

Top Holdings of Tata India Pharma & Healthcare Fund Direct Growth as on (28-Feb-23)

  • Equity

Equity Holdings27

Tata India Pharma & Healthcare Fund Direct Growth: Monthly Changes Updates

All changes are between Dec'22 and Feb'23

Fund Performance

Feb'23
Jan'23
Dec'22
Fund Returns
-3.66%
-1.61%
-3.37%
Nifty 500
-2.22%
-3.79%
-3.47%
  • This fund’s returns stands at -3.66% whereas the fund’s underlying benchmark Nifty 500 returns stands at -2.22% as on Feb'23
  • This fund underperformed Nifty 500 by 1.44% in Feb'23

AUM Change

Parameters
Feb'23
Jan'23
Dec'22
AUM
₹ 485.9 Cr
₹ 503.6 Cr
₹ 515.7 Cr
  • AUM of the fund stands at 485.9 Cr as of Feb'23
  • AUM decreased by 17.7 Cr between Feb'23 and Jan'23

Fund Portfolio Changes

Top Stocks bought last month
Sun Pharmaceuticals Industries Ltd's allocation increased from 18.49% to 19.56%
Sun Pharmaceuticals Industries Ltd's allocation increased from 18.49% to 19.56%
Lupin Ltd's allocation increased from 7.37% to 7.59%
Lupin Ltd's allocation increased from 7.37% to 7.59%
Ipca Laboratories Ltd's allocation increased from 5.19% to 5.36%
Ipca Laboratories Ltd's allocation increased from 5.19% to 5.36%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 12.62 % to 12.23 %
Cipla Ltd's allocation decreased from 12.62 % to 12.23 %
Dr Reddy's Laboratories Ltd's allocation decreased from 7.08 % to 6.97 %
Dr Reddy's Laboratories Ltd's allocation decreased from 7.08 % to 6.97 %
Divi's Laboratories Ltd's allocation decreased from 5.42 % to 5.4 %
Divi's Laboratories Ltd's allocation decreased from 5.42 % to 5.4 %
Large Cap allocation has gone down from 48.3% to 46.3%
Large Cap allocation has gone down from 48.3% to 46.3%
Small Cap allocation has gone up from 18.3% to 18.8%
Small Cap allocation has gone up from 18.3% to 18.8%
Mid Cap allocation has gone up from 32.2% to 33.2%
Mid Cap allocation has gone up from 32.2% to 33.2%
Cash allocation has gone up from 1.2% to 1.7%
Cash allocation has gone up from 1.2% to 1.7%

Top Sector in February was Health

Feb'23
Health
100%
Jan'23
Health
100%

Gainers & Losers in Tata India Pharma & Healthcare Fund Direct Growth portfolio as on (28-Feb-23)

Tata India Pharma & Healthcare Fund Direct Growth Fund Manager

Meeta Shetty

Meeta Shetty

Fund Manager of Tata India Pharma & Healthcare Fund Direct Growth, since 9 March 2021

Fund Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 8.03% since inception which is less than its category average return of 13.52%
Fund Allocations

Fund Allocations

This fund has an allocation of 98.3% in Equity, 0% in Debt and 1.7% in Cash related instruments
AUM size ₹486 Cr

AUM size ₹486 Cr

This fund has AUM of ₹486 Cr which is less than its category average of ₹ 1251 Cr
Expense Ratio 1.01%

Expense Ratio 1.01%

This fund has an expense ratio of 1.01% which is less than its category average expense ratio of 1.56%

Frequently Asked Questions

The current NAV of Tata India Pharma & Healthcare Fund Direct Growth is 17.41 as on 20-Mar-2023.
Existing (Absolute + CAGR)
Tata India Pharma & Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
-3.85%
-3.85%
6 Month Returns
-2.63%
-2.63%
1 Year Returns
-7.52%
-7.52%
3 Years Returns
83.43%
22.41%
5 Years Returns
99.24%
14.78%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
1.01 as on February 2023
486 Cr as on February 2023
Sun Pharmaceuticals Industries Ltd(18.74%),Cipla Ltd(11.29%),Dr Reddy's Laboratories Ltd(7.21%),Lupin Ltd(7.03%),Alkem Laboratories Ltd(6.73%) as on February 2023
The alpha ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
Tata India Pharma & Healthcare Fund Direct Growth
5.24
4.57
7.31
As on February 2023
The alpha for Tata India Pharma & Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
Tata India Pharma & Healthcare Fund Direct Growth
0.97
0.8
0.74
As on February 2023
The Beta for Tata India Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
Tata India Pharma & Healthcare Fund Direct Growth
-0.6
0.79
0.55
As on February 2023
The sharpe ratio for Tata India Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
Tata India Pharma & Healthcare Fund Direct Growth
12.65
19.41
17.9
As on February 2023
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.71 as on February 2023. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.39 as on February 2023. It tells the consistency of the fund in generating superior risk-adjusted performance
Meeta Shetty is the fund manager of Tata India Pharma & Healthcare Fund Direct Growth
The Exit load of Tata India Pharma & Healthcare Fund Direct Growth is 0.25%